Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Paul Fry will now serve as non-executive director of Avacta Group. Most recently, Fry was the interim CEO and chief financial officer at Vectura Group.
Ed Vertatschitsch has been named chief operating officer of Bardy Diagnostics. Most recently, Vertatschitsch was vice president of global portfolio solutions at Varian Medical Systems.
Bavarian Nordic has named Laurence De Moerlooze the firm’s newest executive vice president and chief medical officer. Prior to this appointment, De Moerlooze was vice president and global program lead for vaccines at Takeda Vaccines.
Bijoy Sagar has been named Bayer’s new chief information technology and digital transformation officer. Most recently, Sagar was the chief technology officer at Stryker.
Giuseppe Ciaramella, chief scientific officer of Beam Therapeutics, has been promoted to president of the company. Since February 2018, Ciaramella has served as Beam’s chief scientific officer. Ciaramella was chief scientific officer of Moderna Therapeutics’ infectious disease division prior to joining Beam.
Catalent has announced the appointment Ricci Whitlow to the role of president of clinical supply services, succeeding Paul Hegwood who will retire in March 2020. Most recently, Whitlow was senior vice president of technical and corporate operations at OptiNose.
CBD Emporium, a retailer of cannabidiol products, has named Paul Steinberg as the company’s new chief operating officer. Previously, Steinberg held roles at Abraxis Bioscience (acquired by Celgene), Novella Clinical, PPD and Simbec-Orion.
Rex Clements has been named CEO of Centrient Pharmaceuticals, replacing Karl Rotthier who will step down from the role after leading the company for nearly 10 years.
CytoDyn has announced the hiring of Maura Fleming as the firm’s vice president, general counsel and corporate secretary. Fleming previously held a counsel role at Holland & Hart.
Laurence Reid is now CEO of Decibel Therapeutics, joining the company after spending three years at Warp Drive Bio prior to its takeover by Revolution Medicines in 2018.
Dermavant Sciences has announced the appointment of Chris Chapman to the position of chief commercial officer. Recently, Chapman was vice president and general manager of Galderma.
John Quisel, Acceleron Pharma’s executive vice president and chief business officer, is leaving his role to become CEO of Disc Medicine , a venture-backed biotech startup.
Hollister has appointed Abinash Nayak the company’s newest vice president of Americas. Prior, Nayak was the vice president of marketing, strategy and business development at Hill-Rom.
Horizon Therapeutics has announced the departure of executive vice president of research and development and chief scientific officer Shao-Lee Lin. Several members of leadership within the company will now report directly to Timothy Walbert, president and CEO at Horizon. Members now reporting to Walbert include Elizabeth H.Z. Thompson, group vice president of clinical development and external search; Srini Ramanathan, group vice president of development sciences and San Francisco site head; and Melanie Gloria, senior vice president of R&D operations.
Jørgen Hansen is now CEO of Ivenix, after serving for six years as CEO and president of Cantel Medical.
Amol Soin has been named JanOne’s new chief medical officer. Soin will continue his pain practice from his office in Centerville, Ohio.
Antonio Gualberto is stepping down as head of development and chief medical officer at Kura Oncology. Vice president of clinical development Bridget Martell has been named acting chief medical officer until Kura hires a permanent replacement.
Lantheus Medical Imaging
Lantheus Medical Imaging has announced the hiring of Istvan Molnar, who will take over as the company’s new chief medical officer. Before joining Lantheus, Molnar was chief medical officer at Fusion Pharmaceuticals.
Thomas Slavin has been named senior vice president of medical affairs at Myriad Genetics. Slavin is assistant professor of medical oncology and therapeutic research and population sciences at the City of Hope National Medical Center.
Neuronetics has named Andrew Macan as the company’s chief compliance officer and senior vice president, general counsel and corporate secretary. Macan previously served as senior vice president, general counsel and corporate secretary at US Silica Holdings.
Ian Churcher has been appointed to the role of chief scientific officer at OxStem. Previously, Churcher was senior vice president of drug discovery at BenevolentBio. He also spent 11 years at GlaxoSmithKline as director and head of the protein degradation discovery performance unit.
Passage Bio has named Bruce Goldsmith as the company’s newest CEO. Most recently, Goldsmith was CEO of Civetta, a cancer startup.
Gökhan Batur, chief commercial officer of Polyphor, will now serve as the company’s CEO, succeeding recently retired Giacomo Di Nepi. Prior to Polyphor, Batur served as executive director and global brand leader of antibiotics at Merck.
Poxel has announced the appointment of David E. Moller to the role of chief scientific officer. Before joining Poxel, Moller was the chief scientific officer at Sigilon Therapeutics.
David Roblin has resigned as the chief operating officer, chief medical officer and president of R&D at Summit Therapeutics.
Verrica Pharmaceuticals has appointed Gerard DiGirolamo to the position of vice president of sales. Previously, DiGirolamo held various executive roles at GSK’s Stiefel. Sheila Kennedy was announced Verrica’s newest vice president of marketing, joining the company after serving as vice president of marketing at Onset Dermatologics.
Gaurav Agarwal has been appointed to the role of CEO at Vyaire Medical. Most recently, Agarwal was president and chief operating officer at KCI.